Alar Pharmaceuticals Inc. Stock

Equities

6785

TW0006785009

Pharmaceuticals

End-of-day quote Taipei Exchange 18:00:00 2024-06-25 EDT 5-day change 1st Jan Change
250.5 TWD +2.04% Intraday chart for Alar Pharmaceuticals Inc. 0.00% +19.57%

Financials

Sales 2024 * 120M 3.69M 5.05M Sales 2025 * 32M 984K 1.35M Capitalization 16.4B 504M 690M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 137 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 512 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.71%
More Fundamentals * Assessed data
Dynamic Chart
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan CI
Alar Pharmaceuticals Inc. Approves Dividend Distribution for the Year Ended December 31, 2023, Payable on June 28, 2024 CI
Gilva Therapeutics, INC. announced that it expects to receive TWD 30 million in funding from Alar Pharmaceuticals Inc. CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from United States Patent and Trademark Office CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Japan Patent Office CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Instituto Mexicano De La Propiedad Industrial CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals CI
Alar Pharmaceuticals Inc.(TPEX:6785) added to S&P Global BMI Index CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+2.04%
Current month-12.11%
1 month-8.91%
3 months-19.45%
6 months+21.90%
Current year+19.57%
More quotes
1 week
244.50
Extreme 244.5
262.50
1 month
244.50
Extreme 244.5
296.50
Current year
194.00
Extreme 194
465.00
1 year
116.00
Extreme 116
465.00
3 years
42.80
Extreme 42.8
465.00
5 years
42.80
Extreme 42.8
465.00
10 years
42.80
Extreme 42.8
465.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 16-09-22
Director of Finance/CFO - 19-10-15
Members of the board TitleAgeSince
Chairman - 16-09-22
Chief Executive Officer - 16-09-22
Director/Board Member - 18-08-06
More insiders
Date Price Change Volume
24-06-25 250.5 +2.04% 392 442
24-06-25 245.5 -1.01% 127,922
24-06-24 248 -2.94% 187,595
24-06-21 255.5 +3.44% 673,139
24-06-20 247 +0.20% 152,371

End-of-day quote Taipei Exchange, June 25, 2024

More quotes
Alar Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The Company mainly develops long-acting drugs for the treatment of opioid use disorder, treatment-resistant depression, and Parkinson disease. The main products include ALA-1000, buprenorphine subcutaneous long-acting sustained-release injection, is indicated for indicated for opioid use disorder (OUD); ALA-1300, subcutaneous injection, is indicated for opioid addiction; ALA-3000, ketamine subcutaneous long-acting sustained-release injection, is indicated for treatment-resistant depression (TRD); ALA-4000, apomorphine subcutaneous long-acting sustained-release injection, is indicated for Parkinson disease (PD); and ALA-2000, subcutaneous injection, is indicated for alcohol addiction and opioid use disorder. The Company distributes ALA-1000 and related products to the United States, France, Germany, the United Kingdom, Italy, and Japan markets.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
250.5 TWD
Average target price
290 TWD
Spread / Average Target
+15.77%
Consensus

Quarterly revenue - Rate of surprise